BPharm MSc PhD
Acting Chief Scientific Officer
Dr Wright has a broad range of experience in the pharmaceutical industry spanning 25 years. He spent more than 17 years at CSL working predominantly in regulatory affairs with nearly a decade as Regulatory Affairs Manager.
During this time Dr Wright was responsible for the registration of a number of key products in Australia and the management of regulatory strategy for development projects.
Most recently he was Global Pharmacovigilance Manager and Regulatory Affairs Manager for the Australian and New Zealand operations of Mayne Pharma, a company recently acquired by Halcygen (ASX:HGN).
He has a Pharmacy degree and post-graduate qualifications from University of Sydney and Health Economics qualifications from Monash University, Melbourne. Dr Wright is responsible for leading the clinical and regulatory development team and progressing afamelanotide through to regulatory approval in global markets.
